Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis

Esta versión no es la más reciente

Información

DOI:
https://doi.org/10.1002/14651858.CD010004.pub3Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 03 diciembre 2014see what's new
Tipo:
  1. Intervention
Etapa:
  1. Review
Grupo Editorial Cochrane:
  1. Grupo Cochrane de Fibrosis quística y enfermedades genéticas

Copyright:
  1. Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Valerie Waters

    Correspondencia a: Department of Pediatrics, Division of Infectious Diseases, Hospital for Sick Children, Toronto, Canada

    [email protected]

  • Felix Ratjen

    Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada

Contributions of authors

 Roles and responsibilities

TASK

WHO WILL UNDERTAKE THE TASK?

Protocol stage: draft the protocol

Valerie Waters

Review stage: select which trials to include (2 + 1 arbiter)

Valerie Waters and Felix Ratjen (+ Nikki Jahnke)

Review stage: extract data from trials (2 people)

Valerie Waters and Felix Ratjen

Review stage: enter data into RevMan

Valerie Waters

Review stage: carry out the analysis

Valerie Waters and Felix Ratjen

Review stage: interpret the analysis

Valerie Waters and Felix Ratjen

Review stage: draft the final review

Valerie Waters and Felix Ratjen

Update stage: update the review

Valerie Waters and Felix Ratjen

Declarations of interest

None known.

Acknowledgements

The authors thank Dr Kenneth Olivier of the National Institutes of Health and National Institute of Allergy and Infectious Diseases for additional information regarding the Arikace® trial. We would also like to thank Nikki Jahnke for her assistance in the preparation of this review.

Version history

Published

Title

Stage

Authors

Version

2020 Jun 10

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis

Review

Valerie Waters, Felix Ratjen

https://doi.org/10.1002/14651858.CD010004.pub5

2016 Dec 19

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis

Review

Valerie Waters, Felix Ratjen

https://doi.org/10.1002/14651858.CD010004.pub4

2014 Dec 03

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis

Review

Valerie Waters, Felix Ratjen

https://doi.org/10.1002/14651858.CD010004.pub3

2012 Dec 12

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis

Review

Valerie Waters, Felix Ratjen

https://doi.org/10.1002/14651858.CD010004.pub2

2012 Jul 11

Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis

Protocol

Valerie Waters, Felix Ratjen

https://doi.org/10.1002/14651858.CD010004

Differences between protocol and review

1. Definition of NTM infection

In the protocol NTM infection was defined as "at least one respiratory specimen", this has been changed to the current definition which is the standard definition by the ATS of "at least two respiratory specimens positive by culture for NTM".

2. Secondary outcome measures

A sixth secondary outcome has been added "Quantitative sputum mycobacterial culture". This outcome was included in the original draft of the protocol, but removed following the advice of one of the peer reviewers and the contact editor. When the review authors looked at past and current ongoing RCTs for NTM lung disease, it became apparent that this is one of the main outcomes which is usually assessed and for the CF population (who may not be expected to convert their sputum), may be the most relevant. Hence the outcome has been listed again.

Keywords

MeSH

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.